COST-EFFECTIVENESS ANALYSIS OF ORAL SEMAGLUTIDE AS THE SECOND-LINE AND THIRD-LINE TREATMENT FOR TYPE 2 DIABETES PATIENT

被引：0
|
作者：
Tan, E. C. H. [1 ]
Yang, M. C. [2 ]
机构：
[1] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan
[2] Natl Taiwan Univ, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE15
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    TUMORI JOURNAL, 2020, 106 (05): : 400 - 405
  • [22] Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
    Guzauskas, Gregory F.
    Rind, David M.
    Fazioli, Katherine
    Chapman, Richard H.
    Pearson, Steven D.
    Hansen, Ryan N.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (04): : 455 - 468
  • [23] Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
    Huo, Gengwei
    Liu, Wenjie
    Chen, Peng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [24] Comprehensive analysis of lung adenocarcinoma patients with gefitinib as first-line, second-line and third-line treatment
    Liu, Daoming
    Wang, Fei
    Chen, Xia
    Shi, Hong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (10): : 20171 - 20178
  • [25] Second-line and third-line chemotherapy in malignant gliomas:: Is there a benefit?
    Pace, A.
    Fabi, A.
    Mirri, A.
    Vidiri, A.
    Cianciulli, A.
    Merola, R.
    Galiè, E.
    Maschio, M.
    Jandolo, B.
    Carapella, C. M.
    NEURO-ONCOLOGY, 2006, 8 (04) : 346 - 346
  • [26] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
  • [27] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
  • [28] Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China
    Gu, Shuyan
    Deng, Jing
    Shi, Lizheng
    Mu, Yiming
    Dong, Hengjin
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (10) : 808 - 820
  • [29] Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
    Reifsnider, Odette
    Pimple, Pratik
    Stargardter, Matthew J. D.
    Brand, Sarah
    Desai, Nihar
    Shetty, Sharash
    DIABETES, 2020, 69
  • [30] Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
    Klarenbach, Scott
    Cameron, Chris
    Singh, Sumeet
    Ur, Ehud
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (16) : E1213 - E1220
12345